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ABSTRACT

THE EFFECT OF PROBIOTICS, PREBIOTICS, AND SYNBIOTICS ON INDICATORS OF
LACTOSE INTOLERANCE: A SYSTEMATIC REVIEW

by
Taylor Cameron Roice
June 2021

Abstract
Lactose intolerance disproportionately affects racial minority groups in the United States,
increasing the incidence of calcium deficiency and low bone mineral density in these
populations. The nutritional quality of lactose-containing food products incentivizes the
investigation of long-term treatment options for lactose intolerance. Modifying the gut
microbiome to increase the quantity of lactose-hydrolyzing bacteria in the intestines is a
promising avenue of treatment that merits investigation. Such modification is typically achieved
via consumption of probiotics, prebiotics, or synbiotics in various forms. This systematic review
examined 25 studies measuring outcomes of lactose intolerance in subjects given probiotic,
prebiotic, or synbiotic treatments. Bacterial strains with the greatest degree of evidence for the
reduction of undesirable outcomes of lactose intolerance were Bifidobacterium longum,
Lactobacillus acidophilus, Lactobacillus delbrueckii subspecies bulgaricus, and/or
Streptococcus thermophilus. Inoculated dairy products also showed strong evidence for the
attenuation of lactose intolerance outcomes.
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CHAPTER I
INTRODUCTION
Lactose intolerance is a universal human concern that disproportionately affects several
minority groups in the United States, adversely impacting the incidence of calcium deficiency
and low bone mineral density in these populations. The high nutritional quality of many lactosecontaining food products incentivizes the investigation of effective long-term treatment options
for lactose intolerance. Modifying the gut microbiome to increase the quantity of lactosefermenting bacteria in the intestines is a promising avenue of treatment that merits investigation.
Probiotics and modifications to the gut microbiome have gained support in contemporary
research due to the specificity, longevity, and associated health benefits of the microbial
treatment options available. The emerging field of synbiotics investigates the effectiveness of
pairing probiotic bacteria with supplements that are intended to encourage proliferation of these
lactose-hydrolyzing bacteria in the intestines. Immense variation is possible in the particular
probiotic/prebiotic combination, time-course of treatment, strain, colony-forming units (CFUs),
and method of probiotic encapsulation used in these studies. Emerging evidence suggests that
probiotics, prebiotics, and synbiotic combinations may be effective at alleviating the symptoms
of lactose intolerance, but a thorough statistical analysis of available evidence is necessary to
determine whether these treatments might be effective enough to influence contemporary dietetic
practices or recommendations.
Purpose Statement: The purpose of this systematic review is to generate a summative evaluation
of studies that examine the association between probiotic, prebiotic, and synbiotic treatments and
a reduction in lactose intolerance indicators, with an emphasis on species and strain.
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CHAPTER II
LITERATURE REVIEW
Lactose Intolerance
Summary and Health Implications: Lactose intolerance is the inability or, more commonly, the
reduced ability to digest the milk sugar lactose. Ideally, lactose is either hydrolyzed by the
endogenous lactase enzyme that is produced in the brush border of the small intestine or it is
digested by bacteria in the gut microbiome that produce similar beta-galactosidase enzymes.1
When lactose is not hydrolyzed by the consumer nor processed by bacteria in the small intestine,
common symptoms are flatulence, diarrhea, abdominal pain, cramping, bloating, and nausea.1,2,3
Interestingly, symptoms unconnected to the digestive tract have also been observed, including
eczema, fatigue, headaches, sinusitis, and cardiac arrhythmia.1
These symptoms are understandably upsetting for the consumer, and they can promote
avoidance of lactose-containing products. This moratorium can be difficult to maintain given the
ubiquity and popularity of milk-based beverages, coffee creamers, chocolates, cheeses, butter,
ice cream, and even lactose-based sweeteners used in food manufacturing. Successful avoidance
of such products by lactose-intolerant individuals is associated with increased rates of
osteoporosis, osteopenia, and low bone mineral density.2,3 These effects are ostensibly due to
insufficient calcium consumption. This illustrates the connection between lactose intolerance and
critical measures of human health.
History and Demographics: Lactase enzyme production into adulthood, also called lactase
persistence, is an evolutionarily new development. Soon after agrarian and pastoral Neolithic
societies began to flourish in Europe between 8500 and 6000 years ago, a beneficial mutation
called C/T-13910 emerged in these populations, promoting increased rates of lactase persistence
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in Northern Europeans.4 This genetic bias toward lactase persistence in adulthood still exists
today, as evidenced by lactose intolerance prevalence that is comparatively low (14-28%) among
central and western Europeans and extremely high in Asian Americans (approximately 80-90%),
African-Americans (75-90%), and indigenous Americans (nearly 100%).3,5 Regional prevalence
of lactase persistence is another consideration, as some endogamous or otherwise genetically
homogenous populations can have very consistent and extreme rates of lactase persistence. In
2005, Paul Sherman and his research team5 discovered a 2% prevalence of lactose intolerance in
a sample of Denmark citizens and a 100% prevalence of lactose intolerance in a sample taken
from Zambia. Providing an effective means of promoting lactose digestion in populations
lacking lactase persistence may increase dairy product consumption, attenuate calcium
deficiency, and improve bone mineral density. This is especially critical for traditionally
marginalized populations who, in addition to having greater prevalence of lactose intolerance,
also may have reduced access to affordable healthcare or may lack health insurance entirely.6
Available Treatments: The most common treatment for lactose intolerance that does not require
dietary restriction is ingestion of exogenous lactase enzyme. Lactase enzyme products contain
beta-galactosidases in concentrations that will vary between manufacturers but tend to have
between 3000 and 6000 IU of active lactase enzyme. These pills, capsules, or tablets are intended
to be consumed immediately before a meal and are regarded as effective at hydrolyzing
consumed lactose.7 In key studies of the effectiveness of exogenous lactase enzyme
consumption, both gastrointestinal distress symptoms and breath hydrogen values were
significantly reduced in treatment groups of various ages following a 25g lactose bolus.7,8
Similar commercial lactase products, whether in pill, capsule, or chewable form, were not as
effective at hydrolyzing a larger bolus of 50g lactose,8 though it is unlikely for a typical person to
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consume such a high dose of lactose in one sitting. Limitations of lactase enzyme consumption
include the narrow timeframe in which the product will function6,7 and the requirement that the
lactase be consumed before every lactose-containing meal. Attenuating lactose intolerance via
adjustments to the gut microbiome is another potentially viable treatment option. While much is
known about the requisite microbiology, contemporary studies attempting to investigate this
avenue of treatment tend to have mixed results, and no robust meta-analyses of contemporary
data have been performed. Consequently, there is not yet sufficient evidence as to whether a
specific probiotic, prebiotic, or synbiotic (see Table 1) treatment is effective in reducing lactose
intolerance symptoms.

Table 1. Glossary of Terms
Probiotics
Prebiotic
Synbiotics
Microbiome

Microbiota
Dysbiosis
Metagenome

Live microorganisms that, when administered in adequate amounts, confer a
health benefit on the host9
A substrate that is selectively utilized by host microorganisms conferring a
health benefit9
A mixture comprising live microorganisms and substrate(s) selectively
utilized by host microorganisms that confers a health benefit on the host10
A characteristic microbial community occupying a reasonable well-defined
habitat which has distinct physio-chemical properties. This community is
integrated in macro-ecosystems including eukaryotic hosts, and it can be
crucial for the host’s functioning and health11
The assemblage of living microorganisms present in a defined environment11
An imbalance in the composition and functional capacity of the host
microbiota12
The collection of genomes and genes from the members of (in this context)
the host microbiota13

The Gut Microbiome as a Target of Lactose Intolerance Intervention
Measuring Alterations in the Gut Microbiome: Experimentally researching the gut microbiome
is a laborious and imprecise endeavor. To establish precise causal relationships between bacteria
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and human health, pure axenic cultures of the bacteria must be made, their effects on a host must
be observed, and their biological roles in the human body must be ascertained from this isolated
data. These data are still limited in their external validity because each bacterium lives amid
millions of immediate bacterial neighbors in the small intestine, and each study participant’s gut
microbiome composition will be different. The metabolism of any given bacterium will also vary
based on the host’s nutrition, stool consistency, drug treatments, hydration status, stress level,
and other factors.14
The goal of a probiotic and/or prebiotic intervention, then, is to promote a change in the
gut microbiome of a sufficient magnitude to result in an observable change in the host via stool
samples, breath composition tests, lactose tolerance tests, or perceived symptoms of
gastrointestinal distress over time.14,15 Methods to quantify and describe gut microbiome
composition via stool samples or biopsied small intestine samples include metagenomics and the
complementary approach of culturomics.16 Metagenomics is the practice or field of study
concerned with the analysis and categorization of a microbial metagenome via extraction of
nucleic acids from microbial samples, either via shotgun sequencing of the whole DNA sample
or via polymerase chain reaction and subsequent 16s rRNA sequencing.16,17,18 The results are
then compared to an expanding database of 16s rRNA gene sequences and more broad genomic
profiles intended for shotgun sequencing such as those catalogued by NCBI’s Gene Expression
Omnibus (GEO),19 GenBank,20 and the Genomics OnLine Database (GOLD).21 There is some
contention as to the terminology used in this field; some researchers consider 16s rRNA to be a
type of targeted metagenomics and shotgun sequencing to be shotgun metagenomics,17 while
others do not consider 16s rRNA sequencing to be an application of metagenomics at all.18 In
either case, analyzing the genomic profile of a subject’s intestinal bacteria can provide

5

6

information about probiotic treatment outcomes, at least in terms of colonization. There are
drawbacks to this approach, however. A sufficient quantity of high-quality nucleic acid samples
are required for metagenomic analysis, and the quality of samples may vary between extraction
methods.17,18 There is also some difficulty achieving sufficient sequence coverage for minority
bacterial populations, so metagenomic analyses are not always sensitive enough to detect
bacteria that are present in small quantities due to this “depth bias”.17,22 Sorting genes of interest
into orthologous groups during a metagenomic analysis can help researchers avoid some of these
issues and glean useful data about the subject’s gut microbiome composition, as demonstrated in
2011 by M. Arumugam et al.23 Still, depth bias presents identification issues, as does the amount
of “microbial dark matter”, or unassigned gene sequences, yet to be described and identified by
metagenomics.16 This highlights the benefit of performing a mixed-methods analysis of fecal
samples. Such mixed-methods analyses may include elements of both metagenomics and
culturomics.
Culturomics is the field of study concerned with culturing microorganisms from a
bacterial or fungal sample in order to collect data about the physical, chemical, and metabolic
properties of an organism or of the organisms in a microbiome. Methods of bacterial
identification and description intrinsic to culturomics include liquid and solid culture media,
gram staining, fluorescent molecule staining, electron microscopy, carbohydrate utilization tests,
enzyme function tests, and matrix-assisted laser desorption ionization-time of flight mass
spectrometry (MALDI-TOF MS).16,17,22,24 MALDI-TOF MS is a method of bacterial
identification valued for its speed and cost-effectiveness15 and it is sometimes preferred over
identification via 16S rRNA sequencing.25 Through culturomics, researchers have been able to
expand knowledge of the human gut microbiome, reduce the breadth of microbial dark matter,
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and gradually refine and optimize ideal culture conditions for the growth of previously
uncultured species.16,22,26
The efficacy of the synthesis of metagenomics and culturomics has been demonstrated in
a study of dysbiosis in Clostridium difficile infection in which the researchers cultured 112 new
bacterial species27 and observed little overlap between species detected by metagenomics and
those detected by culturomics. A study examining fungal populations in the human gut
mycobiome (fungal microbiome) observed the same small overlap between species detected by
metagenomic methods as compared to culturomics,28 reinforcing the notion that a mixedmethods approach provides more detail about the gut microbiome. Studies investigating the
effect of probiotics and prebiotics may obtain broader outcome data by examining subjects’ stool
samples before and after treatment using both metagenomics and culturomics-based approaches.
Researchers may also benefit from utilizing these approaches with samples taken from the small
intestine, where lactase production and carbohydrate hydrolysis ordinarily take place. In this
review, the methodology by which researchers analyze and describe the outcomes of probiotic
and prebiotic treatment will be considered, with an emphasis on conclusions derived from
mixed-methods analyses.
Hydrogen breath tests, lactose tolerance tests, and subjective measures of gastrointestinal
symptoms of maldigestion are more consistent measuring tools for bacterial activity than stool
samples; measurements can be taken repeatedly over a span of multiple hours and can be used to
ascertain both baseline and endpoint values.29 These outcome variables, in contrast to
metagenomic and culturomic data, are frequently available in the existing literature and were
additional outcomes of interest in this review.
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Mechanisms of Action of Probiotic Bacteria
Overview: The wide genotypic and phenotypic diversity of the human gut microbiome gives
probiotics manufacturers a rich bevy of candidate species to choose from when developing
products, and each species or combination of species may have different avenues through which
they improve human health. The exact number of species present in the gut microbiome is
unknown and is the subject of contemporary research. In early 2019, a research team from the
Wellcome Genome Campus and Centre for Innate Immunity and Infectious Diseases identified
2,505 total intestinal microbial species, including 1,952 uncultured species, using shotgun
sequencing and nucleotide frequency analysis data from 75 different studies to construct
metagenome-assembled genomes (MAGs).30 While this gives some idea of the breadth of
species in the gut microbiome, it might be more practical to look at species that are shared
within-groups to identify a core representative human gut microbiome composition. In the fall of
2019, a research team based out of George Washington University published an analysis of 98
fecal samples from healthy subjects, identifying 155 different bacterial organisms and a
contingent of 84 species that were present in all samples.31 The majority (79.7%) of the 155
species identified belonged to the phyla Firmicutes, Actinobacteria, and Bacteroidetes. This
finding is consistent with the taxa of common probiotic candidates, including various species of
the genus Bifidobacterium from the phylum Actinobacteria and various species of the recentlyreclassified clade of Lactobacillus from the phylum Firmicutes.32,33 The diversity of probiotic
species is reflective of the variety of benefits that these probiotics are intended to have for their
hosts. Benefits of probiotics that pertain to attenuation of lactose intolerance outcomes include
competitive exclusion of potentially pathogenic bacteria, immune modulation, and the
production of beta-galactosidase enzyme.34,35
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Competitive Exclusion and Growth Inhibition of Pathogenic Bacteria: Organisms of different
species that occupy the same ecological niche tend to compete for the limited resources within
that niche, and gut microbes are no exception. Through hydrophobic interactions with the host’s
intestinal lining, acidification of the luminal environment, and the production of specialized
proteins, probiotic bacteria are able to adhere to the gastrointestinal tract and prevent the
adhesion of pathogenic bacteria.35 In this way, probiotic bacteria have been shown to inhibit the
intestinal cell adhesion and colonization of Salmonella typhimurium, Clostridium sporogenes,
and Enterococcus faecalis.36 Lactobacillus and Bifidobacterium species are particularly good
candidates for promoting competitive exclusion due to the mucin-binding proteins and
fibronectin-binding proteins that are characteristic of these species, a prime example of which is
Lactobacillus rhamnosus, which has a mucin-binding protein on the tips of its pili.37 Recently, it
has also been proposed that probiotic bacteria may interfere with a type of communication called
quorum sensing among pathogenic bacteria by inhibiting and degrading signaling molecules in
the human gastrointestinal tract.38 This mechanism of pathogenic inhibition has shown efficacy
in reducing the population of pathogenic Aeromonas hydrophila in the intestines of goldfish.39
Aside from adhering to the intestinal wall and facilitating the interruption of quorum
sensing, some probiotic bacteria also practice competitive exclusion by producing antimicrobial
proteins called bacteriocins.34,36 A prime example is the production of plantaricin by
Lactobacillus plantarum; plantaricin is deadly to many bacteria associated with foodborne
illness, including multiple species of the genera Staphylococcus and Listeria.40 Similarly,
Lactococcus lactis produces the bacteriocin nisin, which has been shown to be antagonistic to the
gram-positive bacteria Bacillus cereus and Staphylococcus aureus, as well as the gram-negative
bacterium Salmonella thyphimurium.41 This is of particular interest because gram-negative
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bacteria are typically resistant to the effects of bacteriocins.42 Probiotic bacteria have a wide
variety of avenues through which they might practice competitive exclusion. Contemporary
research of these antimicrobial and anti-pathogenic properties of probiotics make them a
promising treatment candidate for lactose intolerance, as they may confer some benefit against
foodborne illness in addition to improving the digestibility of lactose-containing products.
Immune Modulation: In addition to the competitive exclusion of potentially pathogenic bacteria,
some probiotic bacteria have been shown to affect the host’s immune system. The same
mechanism of adhesion to intestinal epithelial cells described above allows probiotic bacteria to
remain adjacent to the glycocalyces of intestinal epithelial cells, where microbial metabolites,
signaling proteins, and cell-surface molecular patterns exert an influence on specialized pattern
recognition receptors (PRRs), including toll-like receptors.43 Responses of the intestinal
epithelium and the immune cells of the lamina propria include the reinforcement of tight
junctions, the stimulation of dendritic cells, and the production of interleukins and
cyclooxygenases. This innate immune response has been shown to prime adaptive immune
responses by modulating CD4 T-cell generation and activity.44 For example, a dose of 5E9 CFUs
of Lactobacillus casei fed to Lewis rats 3 times per weeks for several months resulted in a
statistically significant reduction in CD4+ T-cells responsible for producing tumor necrosis factor
alpha (TNF-α) and a statistically significant increase in CD4+ T-cells responsible for producing
the anti-inflammatory cytokine interleukin-10.45 The rats in this treatment group experienced
significantly fewer clinical signs of collagen-induced arthritis, including paw swelling, which
indicates a systemic effect on inflammatory response that was not localized to the intestines.
A later study investigated the effect of a combined probiotic containing Bifidobacterium
bifidum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus reuteri, and Streptococcus
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thermophilus on intestinal inflammation in BALB/c mice. Numerous in vivo and ex vivo
experiments were performed, and the research team discovered that administration of 5E8
CFUs/day of the combined probiotic over 20 days induced CD11c+ regulatory dendritic cells,
which generated CD4+Fox3+ regulatory T-cells that had an anti-inflammatory effect on the
intestinal cells of mice with inflammatory bowel disease.46 This research is promising in that it
shows a pronounced effect on immune and inflammatory responses from a relatively short
course of probiotic treatment, and it reinforces the fact that probiotics have varied and diverse
effects on the gastrointestinal tract.
The wide variety of these effects necessitates caution when interpreting the results of
lactose intolerance interventions. In 2009, an exceptionally thorough systematic review revealed
that probiotics can have an effect on lactose intolerance symptoms such as diarrhea and colitis in
either the presence or absence of lactose intolerance.47 In short, some probiotics which are
hypothesized to alleviate lactose intolerance symptoms may do so through mechanisms that have
little, if anything, to do with improving carbohydrate digestion. This may help to explain why
some probiotic treatments result in a reduction in lactose intolerance symptoms with no
significant changes in hydrogen breath test values.29
Lactase Enzyme Production: Improving carbohydrate digestion is typically the primary aim of
lactose intolerance interventions, unless the chosen intervention is the avoidance of lactosecontaining foods. In addition to competitive exclusion of potentially pathogenic bacteria and the
modulation of the host’s immune system, many probiotic bacteria that are intended to alleviate
lactose intolerance symptoms are selected because they produce beta-galactosidase, or lactase
enzyme, which hydrolyzes lactose into glucose and galactose. This sounds like a straightforward
and logical solution to lactose intolerance, particularly in alleviating the osmotic load presented
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to the colon by undigested lactose, but this mechanism is complicated by the observation that
gases produced by colonic bacteria from fermented carbohydrates also contribute to lactose
intolerance symptoms such as bloating, flatulence, and borborygmi.48 Also, a 28-subject study
conducted in 2005 investigated the microbial compositions of subjects’ fecal samples and
discovered that there was no significant difference in the prevalence of beta-galactosidase
producing bacteria in the samples of lactose-intolerant subjects as compared to lactose-tolerant
subjects.49 Interestingly, there was also no correlation between the prevalence of betagalactosidase producing bacteria and beta-galactosidase activity. Again, this hints at the
complexity of the interplay between probiotic bacteria and lactose intolerance outcomes; simply
providing the host with probiotic bacteria that can produce lactase enzyme may not reliably and
significantly alleviate lactose intolerance symptoms.
Still, lactase production is a desirable quality in probiotic species intended for lactose
intolerant individuals. Lactase producing bacteria that are generally recognized as safe include
Bacillus licheniformis, Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus
acidophilus, Lactobacillus delbrueckii subspecies bulgaricus, Lactobacillus helveticus,
Lactobacillus reuteri, Streptococcus thermophilus, and many others.50,51,52 Some molds such as
Aspergillus phoenicis have also been shown to produce lactase enzyme,53 but they are typically
just used for the production of commercially available exogenous lactase products and are less
common as probiotic candidates. Normally, the host’s endogenous lactase production occurs in
the jejunum and, to a lesser extent, the ileum, and this is where the hydrolysis of lactose and
absorption of the resultant glucose and galactose occur.54 Though bacteria populate the colon
significantly more densely than the small intestine, the ideal site of colonization for a probiotic
intervention that produces lactase enzyme would be the small intestine,55 as both unabsorbed
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carbohydrates the reach the colon and the gaseous products produced by colonic bacteria
contribute to lactose intolerance symptoms.48 In order to assess whether the effect of a probiotic
or prebiotic intervention on lactose intolerance outcomes was due to lactase enzyme activity, the
lactose tolerance test is preferred to the hydrogen breath test,56 as the lactose tolerance test
measures a change in blood glucose in response to a bolus of lactase. An increase in exogenous
lactase production by probiotic bacteria in the small intestine may allow the host to absorb the
products of lactose hydrolysis and thus will impact blood glucose. This is preferable to the
fermentation of carbohydrates in the colon, which does not allow the host to absorb glucose or
galactose.
Mechanisms of Action of Prebiotics and Synbiotics
As a reminder, prebiotics are substrates that are selectively utilized by the host’s
microbiota to confer a health benefit upon the host,9 while synbiotics are combinations of
probiotic and prebiotic treatments that confer a health benefit upon the host.10 Prebiotics are
intended to be digested by gut bacteria, so common candidates for research are polysaccharides
and oligosaccharides that humans cannot digest such as inulin,57 fructo-oligosaccharides,
galacto-oligosaccharides, trans-galacto-oligosaccharides,58 raffinose, stachyose,59 and fucosyloligosaccharides.60 The host’s gut microbiome composition changes in response to the diet, but
prebiotics allow the host to make deliberate and targeted modifications. When the
gastrointestinal tract is consistently exposed to the same carbohydrate sources, bacteria that favor
these carbohydrate sources tend to flourish in a process that is, in this context, called
adaptation.61,62 Adaptation of the gut microbiome in response to prebiotics may then exert the
same mechanisms of action (competitive exclusion, immune response modulation, and enzyme
production) described above.
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Of particular interest is the administration of specific formulations and doses of prebiotics
to elicit a reliable change in the prevalence of particular species of bacteria, but adaptations in
the gut microbiome are reported more broadly as genus-wide changes. This is especially evident
in the “bifidogenic effect” of fructo-oligosaccharides, and galacto-oligosaccharides.63 As early as
1990, it was shown that consuming 10g of raffinose and stachyose daily for 3 weeks increased
participants’ fecal concentrations of bifidobacteria, but no specific species were evaluated in
vitro.64 In vivo, however, this same raffinose and stachyose prebiotic was shown to be fermented
as effectively as glucose by Bifidobacterium longum, Bifidobacterium breve, and
Bifidobacterium infantis, but less effectively by Bifidobacterium bifidum. Pathogenic bacteria
including Clostridium perfringens, Escherichia coli, and Clostridium difficile did not ferment the
prebiotic, indicating the benefit of selective substrate utilization in microbial dynamics such as
competitive exclusion.64 More recently, a research team from the Department of Microbiology
and Immunology in Leuven, Belgium, observed a modest increase in populations of
Bifidobacterium and Anaerostipes species in the gastrointestinal tracts of subject who were fed
inulin.65 It may be the case that species-level adaptations are much more easily achieved via
probiotic use, whereas prebiotics tend to have a significantly less targeted effect.
Synbiotics seek to combine probiotic bacteria and the prebiotics that are best-suited to
those bacteria. There is some evidence that inulin and/or fructo-oligosaccharides may help
support probiotic species such as Lactobacillus paracasei and Bifidobacterium bifidum,66 but few
studies examine alterations of the gut microbiome in response to synbiotic treatment. An in vitro
study conducted in 2016 investigated the fermentative capacity of five Lactobacillus species and
2 Lactococcus species and discovered that, of the xylo-oligosaccharides, xylobiose was
fermented the most effectively, particularly by Lactobacillus acidophilus.67 Though this research
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may not generalize well to the complicated bacterial milieu of the gut microbiome, analyzing the
effectiveness with which probiotic bacteria ferment particular oligosaccharides may give some
insight as to which prebiotics will pair best with which probiotics. Ostensibly, this synergy may
improve probiotic colonization and the capacity for competitive exclusion of pathogens.
Contemporary Research
Recent systematic reviews of the topic have either revealed inconclusive68 or overall
positive69,70,71 results, but these investigations tended to be limited by their heterogeneity of
outcome variables, small quantity of included studies, small sample sizes of included studies,
methodological heterogeneity, and lack robust statistical models examining the available data.
A 2005 systematic review examining the effect of probiotic supplementation on
participants’ hydrogen breath test values or lactose intolerance symptom scores reported
inconclusive results.68 The researchers searched AMED and Medline databases for relevant
studies, and they called and emailed researchers and Lactobacillus probiotic manufacturers to
locate additional studies. A lack of standardized data prevented a pooled statistical analysis of
the 10 included studies, and the small sample sizes of the studies (from 5 to 20 participants) may
have promoted an increased incidence of type II errors among the study results. Of the 9 studies
measuring hydrogen breath test values, an equal number reported positive, negative, and mixed
outcomes. Of the 7 studies measuring symptom outcomes, one returned positive results, five
returned negative results, and one returned mixed results.68 The researchers concluded that strain,
concentration, and duration of wash-out period might affect the measured outcomes. A robust
statistical analysis should ideally stratify the data by these variables to examine their effect on
the outcomes of interest.
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The 2012 textbook Probiotics contains a chapter specifically addressing the use of
probiotics to alleviate lactose intolerance symptoms. This chapter describes bacterial species
known to increase β-galactosidase activity in the feces, including Bifidobacterium breve,
Bifidobacterium longum, and Lactobacillus casei.69 Antibiotics are included as a potential
confounding factor in the effectiveness of probiotic treatments, which indicates that recent and
ongoing antibiotic use would be a sensible exclusion criterion for probiotic trials. The authors
concluded that probiotics provide a promising avenue of treatment for lactose intolerance
symptoms, and there is evidence that some strains of bacteria are effective, but further research is
needed.
A 2018 systematic review examined studies that investigated the effects of probiotic
supplementation on a variety of outcomes, particularly outcomes pertaining to symptoms of
lactose intolerance. Databases and catalogues used included PubMed, Google Scholar, Ovid
MEDLINE, Web of Science, Food Science and Technology Abstracts, Cochrane Central
Register of Controlled Trials, Current Contents Connect, and Clinicaltrials.gov.70 Of the 94
unique full-text clinical trials assessed, 15 were included in the review, and a total of 8 bacterial
species were investigated in the selected studies. The researchers reported mixed results but an
overall positive trend of reduction in the incidence and severity of lactose intolerance symptoms,
though these results varied between species. Bacteria displaying moderately strong evidence for
relief of one or more lactose intolerance symptoms included Bifidobacterium longum,
Bifidobacterium animalis, and Lactobacillus rhamnosus, with the caveat that consumption of
Lactobacillus rhamnosus probiotics may have adverse side effects for populations with poor
immune function.70 By contrast, the researchers concluded that there is insufficient evidence to
support probiotic supplementation using Lactobacillus bulgaricus, Lactobacillus reuteri,
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Lactobacillus acidophilus, Saccharomyces boulardii, and Streptococcus thermophilus to
alleviate lactose intolerance symptoms.70 In the case of Lactobacillus reuteri, the two clinical
trials that were examined yielded positive results, but more studies are necessary to provided
definitive evidence of its effectiveness. Many of these studies were limited in sample size and
duration, and no statistical analysis was performed. Similar to previous systematic reviews, this
research highlights the need for a robust statistical analysis that pools available data and stratifies
outcome variables by bacterial species to offer a clearer measure of the effectiveness of a given
probiotic treatment.
More recently, a systematic review published in 2020 examined 9 studies investigating
the effects of prebiotic and/or probiotic supplementation on a reduction in lactose intolerance
indicators and found an overall positive trend. The researchers drew the studies from PubMed
and SCOPUS databases, then they manually searched the bibliographies of these studies for
additional resources.71 Statistically significant reductions in hydrogen breath test values and/or
lactose intolerance symptom scores were reported in studies of probiotics that contained
Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus reuteri, Lactobacillus
rhamnosus, Bifidobacterium longum, and Streptococcus thermophilus, while the study
examining the effect of Lactobacillus plantarum and Bifidobacterium animalis did not show
significant results.71 Of the 9 studies included, only two were discussed in the aforementioned
2018 systematic review, and the findings concerning the effectiveness of L. acidophilus, B.
animalis, and L. reuteri differed between the two reviews.70,71 This may be due to the differences
in database search methodologies and outcome variables measured in these reviews, and it
indicates that a more inclusive literature search could be performed.
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CHAPTER III
METHODS
Protocol and Registration
This systematic review was conducted following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) checklist,72 and the study rationale and
methodology were prospectively submitted to PROSPERO.
Inclusion Criteria
A study was eligible for inclusion in the systematic review if it met the following criteria:
(1) Human participants in a treatment group received probiotic and/or prebiotic supplementation
of a specified dosage. Genus and species of the probiotic(s) and/or chemical name(s) of the
prebiotic(s) were identified. (2) Human participants in a control group received a placebo that
was unlikely to substantially affect gut microbiome composition or participants’ pre-test and
post-test results were evaluated. (3) The outcomes of interest included any indicator of lactose
maldigestion or lactose intolerance. (4) The study excluded participants with gastrointestinal
diseases, cancer/chemotherapy, antibiotics, milk protein allergy, and/or those who were taking
medications that may affect gastrointestinal motility or microbiome. One exception to this
criterion is IBS with concomitant lactose intolerance, as this is a clinically relevant subgroup of
lactose intolerant individuals and does not preclude their participation in lactose intolerance
research. (5) The study was peer-reviewed, and its full text was accessible.
Literature Search
Search databases included SCOPUS, MEDLINE, WORLDCAT, EMBASE, Web of
Science, Cochrane Library, NIH-HMP studies, and Central Washington University’s OneSearch.
The initial search string used was (Probiotic* OR prebiotic* OR synbiotic* OR “beneficial
bacteria”) AND (“Lactose intolerance” OR “lactase nonpersistence” OR “lactase deficiency”)
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AND (“Lactose intolerance symptoms” OR bloating OR gas OR flatulence OR diarrhea OR
“gastric distress” OR indigestion) NOT (rat* OR mice OR mouse). An additional search was
performed using the terms Lactobacillus, Bifidobacterium, probiotic*, prebiotic*, synbiotic*,
“lactose intolerance”, Saccharomyces boulardii, and Streptococcus thermophilus.
Review papers and reference lists were also examined for suitable studies. Searches were not
limited by language. Studies written in non-English languages were translated to English via the
Linguee database, and any unclear translations were cross-referenced with SDL Trados Studio
translation software.
Study Selection
Eligible studies were sorted to eliminate duplicates, then the titles and abstracts of the
eligible studies were examined to determine whether they fulfilled all of the above inclusion
criteria. In the event of ambiguity or significant threats to internal validity, suitability for a
study’s inclusion in the review was determined by committee to minimize selection bias.
Selected studies were read in full and further evaluated for inclusion, again based on the above
criteria.
Quality Assessment and Data Gathering
Data gathering was conducted according to the Cochrane training manual73 methodology.
A study quality and risk of bias assessment was performed according to the Cochrane Revised
Tool to Evaluate Risk of Bias in Randomized Trails,74 also known as the RoB 2, while cohort
and case-control trials were to be assessed via the 9-point Newcastle-Ottawa Scale.75
Statistical Analysis
Due to significant methodological heterogeneity in the included studies, statistical
analysis was planned but not performed. Cochrane Library’s RevMan 5.4.1 software was to be
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used for all stages of statistical analysis. Potential publication bias was to be assessed via Begg’s
funnel plots, and Egger’s linear regression test was to be used to evaluate heterogeneity.
Additional assessments of heterogeneity would include an I2 calculation and the Q statistic at a
level of significance of P < 0.10. A pooled Chi-square analysis was to be performed on the
lactose intolerance symptom score data, and a comparison of pooled means was to be used to
evaluate the hydrogen breath test data, adjusted for age, sex, and dietary intake. A randomeffects model was to be used.
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CHAPTER IV
RESULTS
The search string yielded a total of 1,411 search results comprised of 1,046 items from
Central Washington University’s OneSearch database, 75 from PubMed, 257 from WorldCat, 33
from Cochrane Library, and 0 from the NIH Human Microbiome Project. Of these items, 135
duplicates were eliminated. When duplicates were eliminated, only the most recently-updated
item was retained so that revised papers would be preferentially spared. In an abstract review of
the remaining 1,276 results, 978 were eliminated for not matching the relevant study parameters,
including 922 studies investigating unrelated topics and 56 studies without interventions or
treatments. The studies investigating unrelated topics primarily featured investigations of other
GI disorders causing similar symptoms, so when this systematic review is updated or replicated
it may be useful to update the search string to dis-include terms such as “irritable bowel
syndrome”, “Clostridium difficile infection”, “radiotherapy”, “chemotherapy”, and “small
intestinal bacterial overgrowth”. Of the remaining results, 275 were somewhat relevant and were
considered for citation mining and for potential inclusion in a review of relevant literature, and
23 were read in full and considered for inclusion in the review after an evaluation of their
methodologies (see Figure 1). Citation mining uncovered 2 additional studies, so 25 studies were
included in the review.76-100
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Figure 1: Flow diagram of study selection process including records identification, eligibility assessment, citation
mining, and total number of studies included (n = 25)

Cochrane Risk-of-Bias Assessment
The RoB 2 is a risk-of-bias assessment tool that evaluates studies for their degree of bias along
the domains of selection, adherence, outcomes, measurements, and reporting. Possible
evaluations for each domain are either “low risk of bias,” “some concerns,” or “high risk of
bias.”74 Of the 25 studies included in the systematic review, 9 featured some concerns in the
selection domain, primarily due to unspecified or nebulous methodology regarding recruitment
of subjects.78,81,84,86,88,89,91,92,96 The adherence domain evaluates both adherence to study protocols
and blinding. Only 5 studies showed some concerns due to a lack of blinding,76,82,84,90,95 while
one study showed high risk of bias in this domain due to a failed attempt at blinding, wherein the
majority of participants could differentiate between cow’s milk and soy milk.97 Several studies
22

23

featured unclear methodology regarding dissemination of outcome data,76,78,91 but risk of bias
was assessed as low. In the measurement domain, one study showed high risk of bias due to a
likely carryover effect,88 while another study showed a carryover effect but adjusted for it.92
Other causes for concern were the use of a 50g lactose bolus82 and the allowance of caffeine
during testing.84 All but one study showed low risk of bias in the reporting domain. This study
relied on unpublished research to evaluate the effect of a probiotic treatment,78 so risk of bias
was considered high for this domain. For any study and domain not referenced above, risk of
bias for that domain was assessed as low. No study had a high overall risk of bias.
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CHAPTER V
SYSTEMATIC REVIEW
The treatments utilized for each study and the primary study results and conclusions are
described in Table 2 below, then this is followed by a narrative synthesis and systematic review
of the included studies.

Table 2. Key Characteristics and Conclusions of Probiotic Studies
Research Team
Almeida et al

Year Sample Treatment(s)
2012 27
2E7-2E9 CFUs
L. casei Shirota
and 5E7 to 5E9
CFUs
Bifidobacterium
breve Yakult
3x/d for 4
weeks

Cano-Contreras et
al

2020 48

Gingold-Belfer et al 2019 8

Probiotic i3.1:
3E9 CFUs
Pediococcus
acidilactici
CECT7483 and
Lactobacillus
plantarum
CECT7484 and
CECT7485
daily for 8
weeks
Bio-25
probiotic
containing 11
bacterial strains
(see below)
daily for 6
months
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Findings
*Total lactose intolerance symptom
scores were reduced in the treatment
group compared to baseline (p < .01).
*Total breath hydrogen scores were
reduced in the treatment group compared
to baseline (p = .04).
*Total symptom scores and breath
hydrogen scores were still significantly
reduced upon 3-month follow-up (p < .05)
*Total lactose intolerance symptom
scores were reduced in the treatment
group compared to baseline (p < .001).
*46.4% of subjects in treatment group and
0% of subjects in placebo group achieved
50% or greater reduction in total
symptoms relative to baseline.

*Significant reductions in symptom
frequency (p <.05) for bloating,
flatulence, abdominal discomfort, and
constipation, but not diarrhea.
*Breath hydrogen scores trended toward a
reduction over study duration (no
significance
reported).
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
He et al
2008 11
125g yogurt
containing L.
bulgaricus, S.
thermophilus,
and appx 1E8
CFUs B.
animalis per
gram 3x/d, as
well as 2E8
CFUs B.
longum in
capsule 3x/d for
2 weeks
Kim et al
1983 24
5mL/kg body
weight of whole
milk containing
either 0, 2.5E6,
2.5E7, or 2.5E8
CFUs/mL of L.
acidophilus
daily for one
week
Labayen et al

2001 22

25g lactose
from appx
500mL yogurt
containing 1E8
CFUs/g of both
L. bulgaricus
and S.
thermophilus or
500mL
pasteurized
yogurt
containing <
100 CFUs/g of
the same daily
for 15 days
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Findings
*Beta-galactosidase activity in feces was
significantly increased after treatment (p <
.01), but not after 8-day follow-up.
*Total symptom scores were significantly
lower upon follow-up than at baseline (p
< .02).

*Significant reductions in breath
hydrogen were observed in the 2.5E6
CFUs/mL (p < .025) and 2.5E8 CFUs/mL
(p < .01) groups, but not the 2.5E7
CFUs/mL (p > .35) group.

*Significant reductions in total GI
symptoms were observed for lactose
malabsorbers consuming non-pasteurized
yogurt as compared to pasteurized yogurt
(p = .037).
*No significant differences in fecal
weight nor frequency.
*Overall shorter orocecal transit time for
pasteurized yogurt (10.5 hr ± .6)
compared to non-pasteurized (12.1 hr ±
.5)
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
Lin et al
1998 20
Lactobacillus
acidophilus B
or Lactobacillus
bulgaricus 449,
each at 1E8 and
1E9 CFUs/mL
in 400mL 2%
nonfermented
milk consumed
once
Montes et al
1995 20
250mL milk
with 1E10
CFUs L.
acidophilus or
containing 1E8
CFUs L. lactis
and 1E10 CFUs
S. thermophilus
Mummah et al
2014 16
Raw milk,
pasteurized
milk, or soy
milk, each
consumed in
doses of 16oz
days 1 and 8.
Consumption
was 4oz on day
2, increasing by
4oz/d to 24oz
on day 7.
Ojetti et al
2010 60
9,000 standard
units of tilactase
15 minutes
before
hydrogen breath
test (HBT) or
4E8 CFUs L.
reuteri pill 2x/d
for 10 days
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Findings
*Both L. bulgaricus-containing milks
resulted in significant reductions in
hydrogen breath values (p < .05) and
symptom scores (p < .05) compared to
control milk.
*L. acidophilus milk containing 1E9
CFUs/mL resulted in significant reduction
in symptoms scores (p < .05) but no
significant reduction in hydrogen breath
values.
*Both L. acidophilus and L. lactis/S.
thermophilus milks resulted in
significantly lower mean symptom scores
(p < .001 and p < .05, respectively) than
un-inoculated milk.
*Significantly lower breath hydrogen
scores were seen with L. lactis/S.
thermophilus milk (p < .001).
*No significant difference observed
between raw and pasteurized milk in
terms of symptom scores.
*Day 1 peak and AUC breath hydrogen
scores were significantly higher for
subjects consuming raw milk than for
pasteurized milk (p = .01).
*Day 8 AUC breath hydrogen for subjects
consuming raw milk were significantly
lower than day 1 scores (p = .05),
indicating potential microbial adaptation.
*Significant reduction in hydrogen breath
test scores was recorded for both L.
reuteri (p < .01) and tilactase (p < .001)
compared to placebo.
*Significant reduction in clinical
symptom scores was observed for both L.
reuteri (p < .0001 for both) compared to
placebo.
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
Pakdaman et al
2016 38
1E10 CFUs L.
acidophilus
DDS-1 daily for
4 weeks

Rampengan et al

2010 79

4E9 CFUs L.
rhamnosus
Rosell-11 and
L. helveticus
Rosell-52
(“Live
probiotic”)
daily for 2
weeks or Dialac
(“Heat-killed
probiotic”)

Rizkalla et al

2000 24

500g/d fresh
yogurt
containing >
1E7 CFUs/g of
L. bulgaricus
and S.
thermophilus or
pasteurized
yogurt
containing <
100 CFUs/g of
the same daily
for 15 days
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Findings
*Significant reductions in overall
symptom scores were observed in the
treatment group (p = .037) as compared to
the control. Specifically, there were
reductions in abdominal cramping (p =
.012), diarrhea (p = .033), and vomiting (p
= .002).
*Both live and killed L. rhamnosus and L.
helveticus probiotic treatment resulted in
significantly lower hydrogen breath test
scores (p < .001).
* Hydrogen breath test scores of subjects
taking live probiotics were not
significantly different from those taking
heat-killed probiotics (p = .453).
*At baseline, 13.9% of subjects were
asymptomatic. After treatment with either
probiotic 58.2% of subjects were
asymptomatic, but no statistical
significance was calculated or reported.
*Breath hydrogen AUC was significantly
reduced after both fresh and heated yogurt
consumption (p < .001 for both) as
compared to baseline.
*Fresh yogurt had a treatment effect on
baseline HBT values that carried beyond
the washout period, indicating potential
adaptation of the gut microbiome.
*Significantly greater increases in plasma
butyrate concentrations were observed for
fresh yogurt as compared to pasteurized
yogurt (p < .03).
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
Roškar et al
2017 44
5E9 CFUs L.
plantarum
MP2026 and
5E9 CFUs B.
animalis IM386
daily for 6
weeks

Ruchkina et al

2013 60

Saltzman et al

1999 18

1E7 CFUs B.
longum and
1E7 CFUs E.
faecium 3x/d in
addition to
standard mesim
forte therapy
daily for 2
weeks
1E10 CFUs L.
acidophilus
BG2FO4 2x/d
for 7 days, with
or without
40mg daily
omeprazole
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Findings
*Significant reductions in the incidence of
diarrhea (p < .05) and severity of
flatulence were observed for the treatment
group.
*Significant reductions in abdominal pain
(p < .01), flatulence (p < .01), and
boborygmi (p < .05) were observed for
the placebo group.
*While symptom scores generally trended
toward improvement, no statistically
significant difference was found between
the probiotic and placebo groups,
indicating a strong placebo effect.
*Significant reduction in HBT scores
compared to baseline (p < .01) in the
treatment group.
*Significant reduction in bacterial
overgrowth syndrome in treatment group
(p < .01) and 70.8% of participants
experienced a return to eubiosis.

*No significant difference in HBT AUC
from baseline values for either
omeprazole or non-omeprazole group.
*No significant differences in total or
individual symptom scores from baseline
values for either group.
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Table 2 (Continued)
Research Team
Year
Savaiano et al

1991 10

Savaiano et al

1996 15

Treatment(s)

Findings

8 total
treatments:
400mL of
unfermented
2% milk
containing
either 1E7 or
1E8 CFUs/mL
of S.
thermophilus
and L.
bulgaricus, or
400mL of 2%
unfermented
milk containing
any of 3 L.
acidophilus
strains at either
1E7 CFUs/mL
or 1E8
CFUs/mL
400mL milk
with 5*108
CFUs/mL B.
longum B6
grown using
lactose, 400mL
milk with 5*108
CFUs/mL B.
longum B6
grown using
lactose and
glucose, or
400mL milk
with 5*108
CFUs/mL B.
longum ATCC
15708 grown
using lactose

*Significant reduction in HBT values
observed in subjects taking L. acidophilus
LA-1 milk at 1E8 CFUs/mL (p < .05) and
S. thermophilus/L. bulgaricus milk at 1E8
CFUs/mL (p < .05) as compared to
control.
* S. thermophilus/L. bulgaricus milk at
1E8 CFUs/mL resulted in a greater
reduction in symptoms than L.
acidophilus milk of the same
concentration.
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*Total breath hydrogen excretion was
reduced for milk containing lactose-grown
B. longum (p = .0001) and milk
containing B. longum ATCC (p = .0128)
as compared to control.
*Milk containing lactose-grown B.
longum also resulted in lower hydrogen
excretion than that of B. longum grown
with both lactose and glucose (p = .0014).
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
Savaiano et al
1997 6
0.6g lactose/kg
body wt/d,
increasing to
0.8g/kg day 3
and 1g/kg day
5, then 1g/kg/d
was consumed
until day 11
Savaiano et al
2013 85
RP-G28
galactooligosaccharide
in escalating
doses for 5
weeks,
beginning at
1.5g/d and
ending at 15g/d

Savaiano et al

2020 377

5g RP-G28
galactooligosaccharide
2x/d for 10d
increasing to
7.5g 2x/d for
20d, or 7.5g
2x/d for 10d
increasing to
10g 2x/d for
20d
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Findings
*Fecal samples taken after lactose feeding
showed appx 33% the rate of hydrogen
gas production as fecal samples taken
after the feeding of a dextrose control, and
this difference was significant (p = .006).

*Both mean and median HBT values
consistently decreased with RP-G28
treatment, but the difference was not
significant.
*Incidence of abdominal pain decreased
significantly compared to placebo (p =
.0288) and the number of subjects
reporting no abdominal pain was
significantly higher than placebo (p =
.019).
*Incidence of bloating and cramping was
reduced as compared to baseline values in
the treatment group, but not significantly
more than placebo.
*There was a significantly greater
incidence of reduction in total symptom
scores with both the lower dose (p = .043)
and the higher dose (p = .029) than the
placebo.
*In both treatment groups, there was a
significantly greater likelihood of
elimination of all GI symptoms (p = .004)
than in the placebo group.
*Treatment groups showed significantly
higher milk consumption upon 30-day
follow-up (p = .008) than placebo group.
*Marked bifidogenic effect: Significant (p
< .05) increases in relative abundance of
Bifidobacterium longum, Bifidobacterium
bifidum, Bifidobacterium breve,
Bifidobacterium catenulatum,
Bifidobacterium angulatum, and
Bifidobacterium gallicum.
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
Turck et al
2020 68
1.8E12 CFUs
B. animalis
subspecies
lactis Bi-07

Vitellio et al

2019 23

Yesovitch et al

2004 10

Findings
*Significant reduction in AUC for
hydrogen breath values in two separate
trials (p = .0012 and p = .0156) as
compared to placebo.
*In one trial, significantly higher odds
ratio of severe nausea was observed for
probiotic as compared to the placebo (OR
4.31) and lactase (6.98).
*No significant reduction in incidence or
severity of GI symptoms observed for
probiotic treatment.
4E9 CFUs B.
*Significant reduction in bloating noted in
longum BB536 treatment group (p = .028) as compared to
and 1E9 L.
placebo.
rhamnosus
*87.5% of subjects initially experiencing
HN001 with
constipation in treatment group achieved
1.4mg vitamin
normal Bristol scores.
B6 daily for 30 *No statistically significant differences in
days
abdominal pain between groups.
*Significant increases (p < .05) in relative
abundance of Slakia, Thricoccus,
Bifidobacterium, and Enterococcus genera
and significant decreases in Klesbiella,
Serratia, and Enterobacter genera were
observed in the treatment group as
compared to placebo.
VSL3 probiotic *No statistically significant reduction in
containing
HBT values nor symptom scores noted in
either 4.5E11 or either treatment group as compared to
1.8E12 CFUs of baseline.
L. casei, L.
plantarum, L.
acidophilus, L.
bulgaricus, B.
longum, B.
breve, B.
infantis, and S.
salivarius daily
for 17 days
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Table 2 (Continued)
Research Team
Year Sample Treatment(s)
Zhong et al
2006 11
125g yogurt
containing L.
bulgaricus, S.
thermophilus,
and appx 1E8
CFUs B.
animalis per
gram 3x/d, as
well as 2E8
CFUs B.
longum in
capsule 3x/d for
2 weeks

Findings
*Beta-galactosidase activity in feces was
significantly increased after treatment (p <
.01), but not after 8-day follow-up.
*Total symptom scores were significantly
lower upon follow-up than at baseline (p
< .02).

Probiotics
Probiotics are live microorganisms that, when administered in sufficient amounts, promote
health benefits. For the purpose of this review, synbiotic treatments that include a probiotic
component are discussed in both this section and the synbiotics section. This allows for a more
comprehensive assessment of the strength of evidence that a given probiotic species may affect
outcomes of lactose intolerance.
Bifidobacterium animalis
Bifidobacterium animalis describes Bifidobacterium animalis subspecies animalis and
Bifidobacterium animalis subspecies lactis, once believed to be two separate species. It, like many of
the bacterial species in this review, is a Gram-positive anaerobe. Though both subspecies have been
studied for their probiotic properties, Bifidobacterium animalis subspecies lactis has been shown to
grow easily in milk and milk-based media.101
Four studies in this review examined the effects of Bifidobacterium animalis on outcomes of
lactose intolerance. Two studies showed a significant reduction in lactose intolerance symptom scores
and improvement in other measures76,79 while two had mixed results.77,78 The studies showing a
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significant reduction in symptom scores were closely related and both featured a treatment of
Bifidobacterium longum capsules combined with 125g yogurt containing Lactobacillus delbrueckii
subspecies bulgaricus, Streptococcus thermophilus and Bifidobacterium animalis each day for 2
weeks. Both research teams noted a Bifidogenic effect of the treatment and a significant reduction in
the incidence of diarrhea as compared to the baseline values.76,79 In one study, the fecal betagalactosidase activity of participants was significantly increased following treatment.76 A 6-week
study investigating the effect of Bifidobacterium animalis subspecies animalis IM386 combined with
Lactobacillus plantarum MP2026 elucidated a significant reduction in the incidence of diarrhea and
flatulence in both the probiotic and control groups as compared to baseline.77 This indicates a strong
placebo effect. The researchers also did not find any significant differences in hydrogen breath test
(HBT) values when compared to baseline values, and there was no correlation between HBT scores
and symptoms. Effects of Bifidobacterium animalis subspecies lactis Bi-07 on lactose digestion were
formally evaluated by the European Food Safety Authority based on the results of two unpublished
studies provided by the health claim applicant. In these studies, the researchers noted significant
reductions in HBT scores in the treatment group as compared to placebo, but no significant
differences in attenuation of lactose intolerance symptoms.78 There was also a carryover effect
observed between groups, so the results may have been marred by the adaptation of participants’ gut
microbiomes to the probiotic treatment. The European Food Safety Authority ruled against the
applicant’s health claim that the Bi-07 strain promoted a clear beneficial physiologic effect.78
Taken together, these findings provide little evidence that Bifidobacterium animalis
supplementation is beneficial to individuals with lactose intolerance, and there may be strain-specific
considerations when conducting research into the potential of either subspecies of this bacterium to
affect outcomes of lactose intolerance. Additionally, the majority of these studies investigated the
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effect of Bifidobacterium animalis combined with other probiotic species or prebiotic treatments, so it
would be problematic to attribute the outcomes of those treatments to Bifidobacterium animalis alone.
Bifidobacterium breve
Bifidobacterium breve is a bacterial species commonly used in probiotics for infants and in IBS
research.102 Three studies in this review examined the effect of Bifidobacterium breve on outcomes of
lactose intolerance. In 2012, the effect of a 4-week supplementation period of Lactobacillus casei
Shirota and Bifidobacterium breve Yakult on lactose intolerance symptoms and hydrogen breath test
values was investigated. The research team observed a significant reduction in both breath hydrogen
and symptom scores compared to baseline values in the treatment group, and the reduction in total
symptom scores was comparable to that observed for lactase enzyme.80 Upon 3-month follow-up,
both lactose intolerance symptom scores and breath hydrogen scores remained significantly lower
than baseline values, potentially indicating a lasting adaptation of the gut microbiome. A longer-term
experiment investigated the effect of a 6-month regimen of the Bio-25 probiotic formula, which
contains the following 11 bacteria: Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium
longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis,
Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, and Streptococcus
thermophilus. Each participant reported a reduction in baseline symptoms, but this was only
statistically significant for bloating and flatulence, but not for diarrhea and abdominal pain.81 Two
participants showed reduced HBT scores such that they were no longer diagnosed as lactose intolerant
after only two months, whereas the other participants saw some non-significant reduction in breath
hydrogen. Though the results of this study are promising, it was a pilot study and was limited by its
small sample size of 8 subjects. Another pilot study measured hydrogen breath test values and
symptom scores in 10 participants after a 17-day treatment with a VSL3 multi-probiotic containing
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Bifidobacterium breve, Bifidobacterium longum subspecies infantis, Bifidobacterium longum
subspecies longum, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei,
Lactobacillus plantarum, and Streptococcus thermophilus. There were no significant reductions in
lactose intolerance symptom scores nor HBT scores, though the study duration was fairly short for
such a large (50g) lactose challenge.82
These studies provide a small degree of evidence that Bifidobacterium breve, when in
combination with other probiotic species, may help attenuate outcomes of lactose intolerance. As with
any study investigating a treatment that is comprised of multiple bacterial species, it is difficult to
determine to what extent Bifidobacterium breve may have affected the outcome and to what extent it
was facilitated by the other bacteria.
Bifidobacterium bifidum
Bifidobacterium bifidum is a key microorganism in neonatal development, and its growth and
prevalence in the gut microbiome are stimulated by human milk oligosaccharides early in life. It has
the capacity to digest oligosaccharides found in mucin, which may allow this bacterium to more
easily colonize the gastrointestinal tract.103 It has also been hypothesized that this digestion of
intestinal mucin may promote increased mucin production by the host and contribute to the epithelial
barrier of the intestines.104
Only one study included in this review investigated the effects of Bifidobacterium bifidum
probiotic consumption on outcomes of lactose intolerance. The treatment was the aforementioned 6month regimen of the multi-probiotic Bio-25, which contains 11 probiotic species. While results
trended toward a reduction in bloating and flatulence, and HBT scores were reduced, it would be
unwise to attribute these effects solely to Bifidobacterium bifidum.81 This was also a pilot study with
an exceptionally low sample size and exclusively female participants, so its results are not very
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generalizable. Substantially more research is needed to determine the effectiveness of this bacterium
at attenuating lactose intolerance outcomes.
Bifidobacterium longum
Bifidobacterium longum is another Gram-positive, rod-shaped anaerobe colonizing the human GI
tract, and taxonomically it is a combination of what were formerly three separate biotypes of
Bifidobacteria: Bifidobacterium infantis, Bifidobacterium longum, and Bifidobacterium suis.105 It has
the ability to digest a diverse range of carbohydrates in the intestines and is a common candidate for
probiotic research.106 Bifidobacterium longum was present in 4 of the aforementioned studies included
in this review. In combination with yogurt containing Bifidobacterium animalis and Lactobacillus
delbrueckii subspecies bulgaricus, daily consumption of a probiotic capsule containing
Bifidobacterium longum subspecies longum for 2 weeks was shown to alleviate diarrhea and promote
a bifidogenic effect,76,79 and to increase fecal beta-galactosidase activity as compared to the control.76
It was also present in the Bio-25 and VSL3 multi-probiotic treatments described previously,81,82 the
former of which was associated with a reduction in lactose intolerance symptoms scores and a trend
toward reduction in HBT values, while the latter showed no reduction in HBT values nor symptom
scores.
Additionally, subjects receiving a 30-day treatment of 4E9 CFUs of Bifidobacterium longum
subspecies longum BB536, 1E9 CFUs of Lactobacillus rhamnosus HN001, and 1.4mg vitamin B6 per
day were observed to have significantly less bloating and a notable bifidogenic effect as compared to
those receiving a maltodextrin and corn starch control.83 The researchers also observed a negative
correlation between the relative abundance of Bifidobacterium in subjects’ feces and the outcomes of
bloating and abdominal pain. Interestingly, the ability of Bifidobacterium longum to attenuate
outcomes of lactose intolerance may also depend on its growth conditions. In another study,
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researchers recorded the effects on lactose intolerance outcomes of one-time consumption of 400mL
lowfat milk either alone as a control, containing 5E8 CFUs/mL Bifidobacterium longum subspecies
longum B6 grown using lactose, 5E8 CFUs/mL Bifidobacterium longum subspecies longum B6
grown using both lactose and glucose, or 5E8 CFUs/mL Bifidobacterium longum subspecies longum
ATCC 15708 grown using lactose. In this context, “B6” refers to the strain of bacterium, not vitamin
B6 or pyridoxal as was the case in the previous study. Participants consuming the milk containing
Bifidobacterium longum subspecies longum B6 that was grown using exclusively lactose experienced
significantly less flatulence and lower HBT scores than the control group,84 and a reduction in HBT
scores was also noted in the group consuming milk inoculated with Bifidobacterium longum
subspecies longum ATCC 15708 grown with lactose. Lastly, researchers investigating the effects of 2
weeks of daily supplementation with Bifidobacterium longum subspecies longum 107 and
Enterococcus faecium 107 in patients with both severe lactase deficiency and dysbiosis discovered
significant differences in the treatment group as compared to the control group. The treatment group
showed both significantly lower HBT scores and a significantly greater percentage of subjects
(70.8%) who were able to establish small bowel eubiosis by the end of the treatment period.85
Of the 7 studies in this review, 6 provided some evidence that Bifidobacterium longum, either
alone or in combination with other probiotic species, may attenuate at least one outcome of lactose
intolerance, while only one showed no significant results. Taken together, these studies provide strong
evidence that Bifidobacterium longum probiotics may be a viable treatment option for lactose
intolerance, but there is substantial heterogeneity in the taxa of Bifidobacterium longum that have
been investigated, so it is as of yet unclear which subspecies or strain may be the best candidate for
further research.
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Enterococcus faecium
Enterococcus faecium is a commensal bacterium that is potentially pathogenic if it overproliferates. It is a common cause of wound infections and urogenital infections, and it can be
especially problematic if it develops vancomycin resistance. Enterococcus faecium is somewhat
similar to Enterococcus faecalis, though the former can’t ferment mannitol.107
As described previously, a study investigating the effect of Bifidobacterium longum subspecies
longum 107 and Enterococcus faecium 107 on HBT scores and re-establishment of eubiosis
elucidated significant differences between the treatment group and control group85. It may be
necessary to screen this bacterium for vancomycin resistance prior to its use as a probiotic agent, and
there is still much room for research as to whether it is of any use in reducing undesirable outcomes of
lactose intolerance.
Lactobacillus acidophilus
Lactobacillus acidophilus is a Gram-positive microaerophilic bacterium that has been studied
extensively for its probiotic properties. As early as 1977, it was demonstrated that Lactobacillus
acidophilus NCFM inhibits the growth of pathogenic Clostridium perfringens, Salmonella enterica
serovar Typhimurium (formerly Salmonella typhimurium), and Staphylococcus aureus, while
Lactobacillus acidophilus 4962 inhibits the growth of Escherichia coli, Salmonella enterica serovar
Typhimurium, and Staphylococcus aureus108. Yogurt is a common vehicle for administering
Lactobacillus acidophilus as a probiotic, though care should be taken not to administer a hypercaloric
diet because this has been associated with weight gain in subjects receiving yogurt-based
Lactobacillus acidophilus treatment109. This is not always the case, however. Researchers may opt for
yogurt-based, powdered, or pill-form probiotics, strain-specific research is often performed, and
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durations of treatment vary greatly, each of which contributes to the diversity and heterogeneity of the
available literature.
Of the 8 studies in this review that investigated the effects of Lactobacillus acidophilus, 2 have
previously been described. The Bio-25 probiotic showed a reduction in lactose intolerance symptoms
and a trend toward HBT score reduction81, while the VSL3 probiotic showed no significant reduction
in either of these measures82. Of the 6 remaining studies, 5 showed some reduction in lactose
intolerance symptoms or HBT scores associated with Lactobacillus acidophilus probiotic treatment,
while one did not.
A crossover study investigating the effect of four treatments 400mL of milk combined with
either Lactobacillus acidophilus B or Lactobacillus bulgaricus 449, each at concentrations of either
1E8 CFUs/mL or 1E9 CFUs/mL, discovered a dose-dependent relationship. The one-time
administration of Lactobacillus acidophilus milk containing 1E8 CFUs/mL failed to significantly
reduce HBT scores or attenuate lactose intolerance symptoms, while milk with a concentration of 1E9
CFUs was associated with a significant reduction in mean lactose intolerance symptom scores but not
HBT scores.86 The subjects were allowed to consume black coffee during the treatment period, which
has been shown to increase the survival rate of intestinal Lactobacillus acidophilus and, particularly
in the case of dark roast coffee, may inhibit the growth of Escherichia coli and Staphylococcus
aureus.110 In another crossover study, supplementation of 1E10 CFUs of Lactobacillus acidophilus
for 4 weeks in a maltodextrin capsule was shown to significantly reduce diarrhea, abdominal
cramping, vomiting, and mean symptom scores upon 25g lactose challenge as compared to the
control, although flatulence scores were somewhat elevated at the end of the treatment period.87 There
were no significant differences in Bristol stool scale or HBT scores.
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In a study of 20 children with lactose maldigestion, subjects received 250mL of milk containing
a total dose of 1E10 CFUs Lactobacillus acidophilus NCFM, the same volume of milk containing
1E10 CFUs Streptococcus thermophilus and 1E8 CFUs Lactobacillus delbrueckii subspecies lactis,
and 250mL of an uninoculated control milk, each one day apart. Only 8 subjects were able to
consume the required amount of each treatment, so these were the only subjects included in the final
analysis. Despite this, mean symptom scores were significantly lower upon consumption of the
Lactobacillus acidophilus milk than the control, while HBT scores were somewhat, but not
significantly, higher.88 In addition to poor rates of completion of the treatment by participants, this
study was limited by the exceptionally short washout period between treatments, such that there is a
high risk of a carryover effect.
Another study of the effect of milks inoculated with Lactobacillus acidophilus on HBT scores
revealed a reduction for 2 of the 3 doses tested. Subjects were fed 10mL/kg body weight per day of
either an uninoculated control milk or milk inoculated with 1E6 CFUs/mL, 1E7 CFUs/mL, or 1E8
CFUs/mL Lactobacillus acidophilus for one week. For subjects of a typical weight, this would
amount to several servings of milk per day. The subjects consuming milk containing 1E6 and 1E8
CFUs of Lactobacillus acidophilus had significantly lower HBT scores than the control, but this
effect was not observed for the dose of 1E7 CFUs/mL.89 The researchers did not detect any significant
differences in lactose intolerance symptom scores, and the study was also limited by the small sample
size of 6 subjects in each group.
Similarly, subjects receiving 2E10 CFUs of Lactobacillus acidophilus BG2FO4 for one week
were observed to have no significant reduction in individual or total symptom scores, and the
researchers conducting this study also noted no significant changes in baseline HBT values.90

40

41

Interestingly, participants in this study self-reported their lactose intolerance, but approximately half
of the subjects were found to be lactose digesters.
Finally, a study investigating the effect of milks inoculated with 2 different doses of 3 strains of
Lactobacillus acidophilus and of yogurt starter culture revealed a strain-dependent effect on HBT
scores. Subjects received 400mL of milk containing Lactobacillus acidophilus LA-1, Lactobacillus
acidophilus LA-2, Lactobacillus acidophilus NCFM, or both Streptococcus thermophilus and
Lactobacillus delbrueckii subspecies bulgaricus, and each probiotic treatment was administered in
concentrations of either 1E7 or 1E8 CFUs/mL. Significant reductions in HBT scores were observed
for milk containing 1E8 CFUs/mL of Lactobacillus acidophilus and milk containing the same
concentrations of Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus.91
There was also a reduction in overall symptom scores in the latter group.
There is a moderate degree of evidence that some strains and doses of Lactobacillus acidophilus
may reduce undesirable outcomes of lactose intolerance. Of the 8 studies in this review, 6 showed a
significant reduction in either HBT scores or lactose intolerance symptoms, and 5 showed a
significant reduction in symptoms. Common limitations of these studies included short washout
periods between trials and small sample sizes. Future research could benefit from more homogeneity
in study duration, strain selection, and dosage to determine the most effective treatment modality.
Lactobacillus delbrueckii subspecies bulgaricus
Lactobacillus delbrueckii subspecies bulgaricus is, like many of the bacteria in this review, a
Gram-positive, non-motile, non-spore forming bacterium. It is commonly used in the production of
fermented dairy products, particularly yogurt,111 and this use of Lactobacillus delbrueckii was briefly
featured in episode 6 of the animated science fiction series Love, Death, and Robots.112 Qualities of
great interest for the probiotic capacity of this bacterium are its constitutive expression of the beta-
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galactosidase producing gene and its inability to digest the galactose monosaccharide upon the
cleavage of lactose.113 Rather than digesting galactose, Lactobacillus delbrueckii subspecies
bulgaricus releases it into its external environment. This is nutritionally relevant in that galactose
exuded into the small intestine by probiotic bacteria may be absorbed by the host and thus may
potentially reduce bacterial gas production.
Of the 6 studies examining the effects of Lactobacillus delbrueckii subspecies bulgaricus on
outcomes of lactose intolerance, 5 have previously been described. Daily consumption of a probiotic
capsule containing Bifidobacterium longum subspecies longum for 2 weeks along with 125g yogurt
fermented using Lactobacillus delbrueckii subspecies bulgaricus and fortified with Bifidobacterium
animalis was shown to alleviate diarrhea and promote a bifidogenic effect,76,79 and to increase fecal
beta-galactosidase activity as compared to the control.76 By contrast, a 17-day study investigating the
effect of the VSL3 multi-probiotic containing Lactobacillus delbrueckii subspecies bulgaricus
discovered no significant difference in HBT scores nor symptom scores as compared to baseline,82
though the 50g lactose challenge may have been a limitation. A single dose of nonfermented milk
containing either 1E8 or 1E9 CFUs of this probiotic bacterium significantly reduced both HBT scores
and total symptom scores as compared to baseline at either bacterial concentration.86 This research
team also noted a moderate degree of bile sensitivity and ease of cell wall lysis in Lactobacillus
delbrueckii subspecies bulgaricus, which likely contributes to host lactose digestion via the release of
endogenously-produced bacterial lactase upon lysis. This contextualizes the increase in fecal betagalactosidase observed in a previous study.76 Also, one-time consumption of 400mL of milk
containing Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus in
concentrations of either 1E7 or 1E8 CFUs/mL was shown to reduce both incidence of lactose
intolerance symptoms and HBT scores at the latter concentration.91 The researchers also noted a high

42

43

lactase enzyme concentration (3 standard units/mL) in the milk inoculated with Lactobacillus
delbrueckii subspecies bulgaricus prior to its consumption. Another yogurt study investigated the
effect of consumption of 500g/day for 15 days of either unpasteurized yogurt containing greater than
or equal to 1E7 CFUs of Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus
thermophilus or pasteurized but otherwise identical yogurt. Outcomes measured included blood
glucose, serum lipids, serum short-chain fatty acids, and HBT scores. In lactose maldigesters, HBT
scores were significantly lower, both initially and also after 15 days of fresh yogurt consumption, as
compared to baseline values, but this effect was not observed for pasteurized yogurt.92 Lactoseintolerant subjects also had significantly higher plasma propionate concentrations after the treatment
period than at baseline, but no other findings were significant for this group.
Taken together, these studies provide moderately strong evidence that Lactobacillus delbrueckii
subspecies bulgaricus probiotics, particularly as a component of either yogurt or probiotic-fortified
dairy products, may be effective at reducing deleterious outcomes of lactose intolerance. In future
research, follow-up symptom score assessments may be useful to determine if these effects persist
beyond the 8-hour window for which outcomes were commonly recorded in the above studies. Due to
its high degree of beta-galactosidase production and activity and its tendency to exude rather than
ferment galactose, this bacterium is an interesting and promising candidate for potential probiotic
treatment of lactose intolerance.
Lactobacillus casei
Lactobacillus casei is a probiotic bacterium that is closely related to Lactobacillus paracasei and
Lactobacillus rhamnosus. It has been studied extensively for its probiotic potential, and it has been
shown to have a high degree of acid-resistance and potential bile salt resistance,114 which may help
protect the bacterium as it travels through the host’s gastrointestinal tract.
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Studies investigating the effects of Lactobacillus casei by itself are rare, as it’s commonly
included in multi-probiotic treatments. In the aforementioned study investigating the effect of daily
consumption of a probiotic containing Lactobacillus casei Shirota and Bifidobacterium breve Yakult
for 4 weeks, the treatment resulted in a reduction in baseline lactose intolerance symptom scores and
HBT values upon completion of the treatment regimen, and these effects persisted in a 3-month
follow-up.80 The Bio-25 pilot study also showed a significant reduction in lactose intolerance
symptom scores after a 6-month treatment with a multi-probiotic containing Lactobacillus casei.81 By
contrast, subjects consuming the VSL3 multi-probiotic containing Lactobacillus casei were not
observed to have any reduction in symptom scores nor HBT values.82
There is a small degree of evidence that Lactobacillus casei may, when combined with other
probiotics, have some effect on outcomes of lactose intolerance, but more research is needed. In
particular, research that investigates the effect of solely Lactobacillus casei on these outcomes in
lactose intolerant individuals would contribute greatly to the literature.
Lactobacillus helveticus
Lactobacillus helveticus is a potentially probiotic bacterium that is closely related to
Lactobacillus acidophilus. While it has not, as of yet, been as extensively researched as many other
probiotics, it has been shown to adhere well to the host’s mucosal layer and to competitively exclude
the pathogenic bacteria Escherichia coli 0157:H7 and Campylobacter jejuni.115 Only one study93 in
this review investigated the effects of Lactobacillus helveticus on outcomes of lactose intolerance in
lactose maldigesters, and its results are not especially generalizable to a larger population. A 2010
study investigated the effects of daily consumption of 4E9 CFUs of Lactobacillus rhamnosus Rosell11 and Lactobacillus helveticus Rosell-52 for 2 weeks on symptom scores and HBT values in children
(age 10-12) with lactose maldigestion as compared to the effect of a heat-killed probiotic. The
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researchers noted a significant decrease in HBT scores and the number of asymptomatic subjects, the
latter of which improved from 13.9% of subjects at baseline to 58.2% of subjects following treatment
of the live probiotic.93 As with Lactobacillus casei, it would be useful to investigate the effect of
Lactobacillus helveticus alone rather than in combination with another probiotic species, and this
study population is not representative of typical lactose maldigesters, so there is not sufficient
evidence to determine the effect of Lactobacillus helveticus on outcomes of lactose intolerance in
typical lactose-intolerant individuals.
Lactobacillus delbrueckii subspecies lactis
Lactobacillus delbrueckii subspecies lactis is similar to Lactobacillus delbrueckii subspecies
bulgaricus in that it’s commonly used in the production of fermented dairy products, especially
yogurt. In the literature, this bacterium should be clearly differentiated from Lactococcus lactis, as
Lactobacillus delbrueckii subspecies lactis was formerly considered the separate species
Lactobacillus lactis, thus “L. lactis” is somewhat ambiguous. In contrast to the bulgaricus subspecies,
the lactis subspecies has retained more ancestral genes pertaining to carbohydrate digestion, and it is
specialized toward absorbing lactose via a phosphotransferase system that excels in lower
concentrations of lactose than the bulgaricus subspecies.113 Despite this method of lactose transport, it
may prove to be a similarly effective probiotic in attenuating undesirable lactose intolerance
outcomes.
This bacterium was present in the Bio-25 probiotic, which has shown some ability to alleviate
lactose intolerance symptoms when taken daily for 6 months,81 and Lactobacillus delbrueckii
subspecies bulgaricus was also used, as part of a yogurt starter culture, to inoculate milk that was
administered to lactose-maldigesting children in 250mL doses. Researchers in the latter study
observed a significant reduction in total lactose intolerance symptoms and HBT scores compared to
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baseline in the lactose-maldigesting children who completed the treatment,88 but full compliance was
only achieved by 8 of 20 children. While results were generally positive for both treatments, these
studies do not provide strong evidence that Lactobacillus delbrueckii subspecies lactis has a reliable
effect on outcomes of lactose intolerance, and more research is needed. It may be useful to include the
bacterium as a component of yogurt or inoculated milk, as is often done with the bulgaricus
subspecies.
Lactobacillus paracasei
Lactobacillus paracasei is, as the name may imply, closely related to Lactobacillus casei, so
much so that they share many of the same properties and have historically been difficult to
differentiate from one another. Like its relatives, this bacterium is commonly used to ferment dairy
products and is a viable probiotic candidate due to its acid resistance and inhibition of the
proliferation of Helicobacter pylori.114 In this review, only the Bio-25 multi-probiotic study
investigated a treatment containing Lactobacillus paracasei,81 so there is little evidence to support its
use as a probiotic to attenuate lactose intolerance outcomes.
Lactobacillus plantarum
Lactobacillus plantarum is a Gram-positive, genetically diverse, aerotolerant bacterium
commonly found in animal products and fermented vegetable foods such as kimchi.116 Due to its
ability to digest lactose and its acid tolerance, it is a candidate bacterium for the digestion of silage
and waste products such as whey that are produced in dairy manufacturing.117 These qualities also
make Lactobacillus plantarum a suitable candidate for lactose intolerance research.
Several studies described above included Lactobacillus plantarum as part of a multi-probiotic
treatment, including the Bio-25 pilot study81 and VSL3 pilot study.82 Additionally, daily consumption
of a probiotic containing 5E9 CFUs of Bifidobacterium animalis subspecies animalis IM386 and
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Lactobacillus plantarum MP2026 resulted in significant reduction in the incidence of diarrhea and
flatulence compared to baseline, but no other symptoms, and HBT scores were unaffected.77 In a 2020
randomized controlled trial, the daily consumption of 3E9 CFUs of Pedicoccus acidilactici and
Lactobacillus plantarum strains CECT7484 and CECT7485 for 8 weeks was associated with a
significant reduction in total symptom incidence and severity scores in the treatment group.94 Nearly
half (46.4%) of the treatment group experienced greater than or equal to 50% reduction in symptoms,
while none of the control group experienced this.
Together, these studies provide a moderately low degree of evidence that Lactobacillus
plantarum, in combination with other probiotic bacteria, may attenuate undesirable lactose intolerance
outcomes. More research is needed, but this bacterium is a promising candidate for probiotic
interventions in lactose intolerant populations.
Lactobacillus reuteri
Lactobacillus reuteri is a commensal bacterium normally present in the human gut that has been
shown to produce antimicrobial peptides and perform competitive exclusion of pathogenic bacteria. It
is adapted to a wide range of conditions and hosts, and it colonizes the proximal GI tract as well as the
colon,118 which sets it apart from many other probiotic bacteria and makes it a promising research
candidate. A 2010 study involving 60 lactose intolerant patients investigated the effects of either 9000
units of lactase enzyme immediately before a lactose challenge or daily consumption of 8E8 CFUs of
Lactobacillus reuteri in pill form 10 days before a lactose challenge. Both treatment groups
experienced statistically significant reductions in total symptom scores, each individual symptom
score, and HBT scores.95 The group receiving lactase enzyme showed significantly lower scores than
the probiotic group, so more research is needed to determine whether Lactobacillus reuteri potentially
represents an equally viable lactose intolerance treatment option.
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Lactobacillus rhamnosus
As mentioned above, Lactobacillus rhamnosus is genetically and functionally similar to both
Lactobacillus casei and Lactobacillus paracasei. One characteristic that makes Lactobacillus
rhamnosus an interesting probiotic candidate is the presence of mucous-binding proteins on the tips of
its pili.37 This bacterium, particularly the GG strain, is commonly used in food manufacturing and has
been studied for its probiotic potential,119 but the interventions included in this review either do not
specify a strain or involve non-GG strains.
The Bio-25 multi-probiotic, which again was associated with some significant symptom
reduction, contained Lactobacillus rhamnosus.81 A synbiotic study investigated the effect of 4E9
CFUs of Bifidobacterium longum subspecies longum BB536, 1E9 CFUs of Lactobacillus rhamnosus
HN001, and 1.4mg vitamin B6 per day on lactose intolerance symptoms and gut microbiome
composition. The researchers observed a negative correlation between the relative abundance of
Bifidobacterium in subjects’ feces and the outcomes of bloating and abdominal pain, a significant
reduction in bloating and constipation, and significant decreases in Klesbiella, Serratia, and
Enterobacter genera in the treatment group.83 Also, as discussed above, daily consumption of 4E9
CFUs of Lactobacillus rhamnosus Rosell-11 and Lactobacillus helveticus Rosell-52 in children from
10 to 12 years of age was associated with a significant decrease in HBT scores and in the number of
asymptomatic subjects.93
Taken together, these studies provide a small degree of evidence that Lactobacillus rhamnosus
probiotics, when in combination with other probiotic species, may attenuate undesirable outcomes of
lactose intolerance. Further research will be necessary to determine which strains and what dosages
are the most effective. It may also be useful to see Lactobacillus rhamnosus studied alone rather than
as a component of multi-probiotic treatments.
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Pediococcus acidilactici
Pediococcus acidilactici is a Gram-positive, sphere-shaped, comparatively resilient bacterium
that colonizes the entire human gastrointestinal tract. This makes it a promising probiotic candidate,
and it has been studied for the potential anti-tumor, immunomodulatory, and antioxidant properties of
its metabolites.120 There is little evidence that Pediococcus acidilactici has an effect on outcomes of
lactose intolerance, however. As mentioned above, an 8-week study investigated the effects of daily
supplementation of Pediococcus acidilactici CECT7483 and Lactobacillus plantarum strains
CECT7484 and CECT7485 on outcomes of lactose intolerance and found a significant reduction in
total symptom scores and symptom severity in the treatment group,94 but substantially more research
is needed to determine to what extent this effect was promoted by Pediococcus acidilactici
specifically.
Streptococcus thermophilus
Streptococcus thermophilus is another Gram-positive, non-spore forming, non-motile anaerobe,
and it is used alongside Lactobacillus delbrueckii subspecies bulgaricus to ferment dairy products.
The two species are mutualistic as they supply one another with amino acids, formic acid, folic acid,
and carbon dioxide for essential metabolic processes.121 It has been studied extensively for its
probiotic properties and for its production of metabolically useful metabolites, including the ability of
the APC151 strain to produce GABA in yogurt.122
As it is commonly found alongside other bacteria, it may be difficult to separate the beneficial
effects of Streptococcus thermophilus from the effects of other probiotics commonly included in
yogurt or fortified into probiotic milks. Consequently, each Streptococcus thermophilus study
included in this review has been described above. Daily consumption of 125g yogurt containing
Bifidobacterium animalis, Streptococcus thermophilus, and Lactobacillus delbrueckii subspecies
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bulgaricus alongside a probiotic capsule containing Bifidobacterium longum subspecies longum for 2
weeks was associated with a reduction in diarrhea, promotion of a bifidogenic effect,76,79 and an
increase in fecal beta-galactosidase activity.76 The Bio-25 multi-probiotic included Streptococcus
thermophilus and was associated with alleviation of some lactose intolerance symptoms.81 Children
with lactose maldigestion who were given 400mL of milk inoculated with 10E8 CFUs Lactobacillus
delbrueckii subspecies lactis and 1E11 CFUs Streptococcus thermophilus showed significant
reductions in total symptom scores and HBT values compared to baseline, although compliance was
poor (40%) for this subgroup.88 A dose-dependent relationship may also exist for this bacterium. A
study investigating the effects of one-time consumption of 400mL of milk inoculated with 1E7
CFUs/mL or 1E8 CFUs/mL of a yogurt starter culture or of various strains of Lactobacillus
acidophilus concluded that higher doses (1E8 CFUs/mL) of the yogurt starter culture containing
Streptococcus thermophilus and Lactobacillus delbrueckii subspecies lactis effectively reduced
lactose intolerance symptoms and HBT values.91 Also, fresh yogurt containing Streptococcus
thermophilus and Lactobacillus delbrueckii subspecies bulgaricus was shown to reduce HBT scores
more than pasteurized yogurt.92
All 6 studies investigating the effects of Streptococcus thermophilus probiotics, yogurts, or
inoculated milks found significant reductions in at least one outcome of lactose intolerance. This
bacterium shows a strong degree of evidence for attenuation of undesirable lactose intolerance
outcomes, with caveat that this effect may be due to any of the other bacteria in the multi-probiotic
treatments that were administered. This is not necessarily problematic, as studying Streptococcus
thermophilus alone, as an axenic probiotic, might remove the mutualistic benefit offered by
Lactobacillus delbrueckii.
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Prebiotics
Prebiotics, as a reminder, are substrates that are selectively utilized by the host’s microbes to
confer a health benefit upon the host, in this context by promoting adaptive changes in the
composition of the gut microbiome.9 These are commonly indigestible carbohydrates, or even poorlydigested carbohydrates such as raffinose and stachyose. In the case of lactose intolerant individuals,
lactose is an indigestible or poorly-digested carbohydrate, so it potentially fits the definition of a
prebiotic, and studies investigating the prebiotic potential of lactose were included in this review.
Studies that investigated the effects of bacterial inoculations, supplementation, or fortification in
combination with lactose or lactose-containing foods were considered synbiotic rather than prebiotic
studies for the purpose of this review. This includes studies in which yogurt was the treatment.
Lactose
There are logistical and potentially even ethical issues with using lactose as a treatment in
lactose-intolerant individuals. Researchers should be mindful of the discomfort, pain, and undesirable
outcomes that will likely be experienced by subjects when this treatment is applied, and substantial
attrition should be expected. Two studies included in this review investigated the effect of either
lactose or milk administered to lactose-intolerant subjects. The first investigated the effect of
increasing doses of lactose on hydrogen gas production and consumption over 10 days. The initial
dose was 0.6g/kg body weight on day 1, which increased to 0.8g/kg day 3 and 1g/kg day 5, which is
equivalent to more than 4 glasses of milk for most subjects. Interestingly, fecal hydrogen production
by each fecal bolus was measured for 24 hours after defecation, and fecal hydrogen production was
significantly lower in the lactose group at 3 hours and 24 hours.96 No breath hydrogen scores were
recorded, nor were symptom scores, but this study does provide some evidence of potential microbial
adaptation to lactose as a prebiotic.
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The second study investigated the effect of raw milk consumption, as compared to pasteurized
milk or soy milk consumption, on breath hydrogen production and lactose intolerance symptom
scores. In a crossover trial, subjects consumed raw milk in doses that began at 16 ounces on day 1,
dropped to 4 ounces on day 2, increased by 4 ounces per day until day 7, then returned to a baseline
dose of 16 ounces on day 8. Hydrogen breath tests were performed in response to the 16-ounce bolus
of milk on days 1 and 8. There was a borderline significant reduction in total and peak hydrogen gas
production by subjects consuming raw milk,97 and these values were comparable to those observed
for consumption of pasteurized milk on day 8. This may indicate some colonic microbial adaptation
to raw milk, but not in excess of that observed for pasteurized milk. No differences in symptom scores
were observed. No evidence was found to support the use of lactose as a prebiotic to attenuate
undesirable outcomes of lactose intolerance.
RP-G28 galacto-oligosaccharide
Two studies included in this review investigated the effect of a novel glacto-oligosaccharide on
outcomes of lactose intolerance. The first investigated the effects of two levels of RP-G28 galactooligosaccharide on symptom scores, number of responders (those with a reduction in symptom
composite score of 4 or greater or those reporting a symptom score of 0), quality of life, gut
microbiome composition, and lactose consumption upon follow-up. In total, 377 subjects were
included and randomized into three groups. One received a corn starch based placebo, one received
5g of the treatment 2 times per day for 10 days then 7.5g of the treatment 2 times per day for 20 days,
and the third group received 7.5g of the treatment 2 times per day for 10 days then 10g of the
treatment 2 times per day for 20 days. There was a 40% response rate to RP-28 treatment and a 26%
response rate to the placebo, and there were significant reductions in abdominal pain, abdominal
cramping, bloating, and gas in the treatment groups as compared to the placebo group.98 Subjects in
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each treatment group also reported consuming significantly more milk per day than they had
previously, and this increase was greater than that seen in the placebo group, potentially indicating an
increase in milk tolerability.98
The second study investigated the effects of the same prebiotic in escalating doses of 1.5g/day to
a maximum of 15g/day over the course of 35 days on HBT scores and lactose intolerance symptoms.
Self-reported dairy consumption and an additional HBT were recorded during a 30-day follow-up.
Compared to the corn syrup placebo, subjects consuming the prebiotic experienced generally, but not
significantly, lower HBT scores.99 Lactose intolerance symptom scores trended toward reduction,
with 72% of the treatment group reporting a reduction in symptoms as compared to 28% of the
placebo group. The number of subjects reporting no abdominal pain by the end of the treatment
period was significantly higher for the treatment group than the placebo group. Subjects in the
treatment group were also significantly more likely to report tolerance of dairy upon follow-up.
Symptom scores, interestingly, were lower upon follow-up than they were at the end of the treatment
period.99 Taken together, these findings indicate some promise for RP-G28’s potential to alleviate
deleterious outcomes of lactose intolerance. Of note is that there was a substantial overlap in the
membership of the research teams conducting these two studies. In the interest of replication, it would
be helpful to see a similar study conducted by an unrelated research team.
Synbiotics
Synbiotics are mixtures of probiotics and substrates selectively utilized by those probiotics that
confer a health benefit upon the host. For the purpose of this review, yogurt was considered a
synbiotic treatment, as was the treatment composed of Bifidobacterium longum subspecies longum,
Lactobacillus rhamnosus, and vitamin B6. Although, strictly speaking, vitamin B6 is ostensibly not
selectively utilized by these bacteria any more than it is by the host, the nature of synbiotic treatment
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generally involves any bacterium combined with a micronutrient or macronutrient intended to support
the probiotic potential of the bacterium, so a more inclusive interpretation of synbiotics will be
applied in this case.
Inoculated dairy products
Inoculated dairy products contain both lactose-hydrolyzing bacteria as well as the nutrient-rich
media in which these bacteria might propagate, both prior to digestion and when they are introduced
to the bacterial milieu of the gastrointestinal tract. In total, 9 studies included in this systematic review
investigated the effect of inoculated dairy products on outcomes of lactose intolerance. Within these
studies, treatments that were associated with reductions in both symptom scores and HBT values were
400mL of milk inoculated with 5E8 CFUs/mL of lactose-fed Bifidobacterium longum B6,84 400mL of
milk inoculated with 1E8 or 1E9 CFUs/mL of Lactobacillus delbrueckii subspecies bulgaricus,86
250mL of milk inoculated with 1E8 CFUs/mL Lactobacillus delbrueckii subspecies lactis and 1E10
CFUs/mL Streptococcus thermophilus administered to children with lactose intolerance,88 and 400mL
of milk inoculated with 1E8 CFUs/mL of Lactobacillus delbrueckii subspecies bulgaricus and
Streptococcus thermophilus.91 Treatments that were associated with symptom score reduction but not
HBT score reduction were 125g yogurt containing Lactobacillus delbrueckii subspecies bulgaricus,
Streptococcus thermophilus and Bifidobacterium animalis combined with a probiotic capsule
containing 2E8 CFUs of Bifidobacterium longum,76,79 as well as a treatment of 25g of lactose from an
unspecified quantity of unpasteurized yogurt containing 1E8 CFUs/g Lactobacillus delbrueckii
subspecies bulgaricus and Streptococcus thermophilus.100 Treatments associated with a reduction in
HBT scores but not symptom scores were 500g/day fresh yogurt containing greater than or equal to
1E7 CFUs/g of Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus,92 as
well as 10mL/kg body weight of milk inoculated with 1E6 and 1E8 CFUs/mL of Lactobacillus
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acidophilus.89 Taken together, these studies provide moderately strong evidence that inoculated dairy
products containing at least 1E8 CFUs/mL of Lactobacillus delbrueckii, particularly subspecies
bulgaricus, and Streptococcus thermophilus may attenuate undesirable outcomes of lactose
intolerance.
Probiotics combined with vitamin B6
One synbiotic study included in this review investigated the effects of 4E9 CFUs of
Bifidobacterium longum subspecies longum BB536, 1E9 CFUs of Lactobacillus rhamnosus HN001,
and 1.4mg vitamin B6 per day on outcomes of lactose intolerance, including symptom scores and gut
microbiome composition. The treatment was associated with a notable Bifidogenic effect and
significantly less bloating as compared to the control.83 This study does not provide conclusive
evidence that vitamin B6 has a synergistic effect on Bifidobacterium longum and Lactobacillus
rhamnosus in vivo, and this treatment option merits further study.
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CHAPTER VI
DISCUSSION
In this systematic review of 25 studies investigating the effects of probiotic, prebiotic, and
synbiotic interventions on outcomes of lactose intolerance, there was a generally positive effect of
nearly all treatments. Only 2 probiotic studies and 2 milk/lactose prebiotic studies showed a complete
lack of significant improvement in any of the outcomes assessed for each included study. One of these
probiotic studies utilized a large bolus of 50g lactose for the lactose challenge after a relatively short
treatment duration,82 and half of the participants in the other probiotic study were found to be lactose
digesters upon closer examination,90 so the lack of significant differences may be explained by the
methodology employed in these studies. Moderately strong evidence for attenuation of lactose
intolerance outcomes was observed for Bifidobacterium longum, Lactobacillus delbrueckii subspecies
bulgaricus, Lactobacillus acidophilus, and Streptococcus thermophilus. A 2018 systematic review
assessing the same outcomes from among 15 probiotic and prebiotic studies also concluded that
Bifidobacterium longum probiotic supplementation showed a moderately strong degree of evidence of
its effectiveness,70 and a similar conclusion was reached in a 9-study 2020 systematic review,71 so this
bacterium may be an especially promising candidate for future lactose intolerance research.
The beneficial effects of the ingestion of lactic acid bacteria used as yogurt starter cultures, e.g.
Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus, are likely due to the
lysis of bacterial cells in the consumer’s stomach and the release of bacterial beta-galactosidase. This
is noteworthy because traditional probiotic benefits are often presumed to come from bacterial
colonization. Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus do not
generally survive passage through the digestive tract, particularly if the product containing the
bacteria is heat-treated.123 Lysis of these bacteria in the stomach and failure to colonize the
gastrointestinal tract would cause the beneficial effects of these bacteria to be short-lived. It would be
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fruitful to investigate the duration of improvement of lactose intolerance outcomes upon ingestion of
inoculated dairy products as compared to ingestion of lactase enzyme pills or capsules.
Bifidobacterium longum probiotics, by contrast, may have a longer-term effect on lactose
maldigestion due to the ability of probiotic capsules to remain intact in the stomach and release their
contents in the intestine.124 In either case, further research is necessary to determine the duration of
the beneficial effects of these probiotic bacteria and the precise mechanisms of action that promote
the observed benefits.
Although a meta-analysis was originally planned, the substantial methodological heterogeneity
between studies included in this review prevented pooling or statistical comparison of results. Studies
varied in treatment dosage, method or schedule of treatment administration, dietary restriction
imposed upon subjects, contents of multi-probiotics administered, duration, follow-up protocols, mass
of the lactose bolus used for the HBT, and scale used to measure or report lactose intolerance
symptom scores. Future studies may benefit from consistency, or even homogeneity, in these
parameters, though few validated methods and agreed-upon values exist for each. The quantity of
lactose for assessing HBT scores is a minor exception. Formerly, this test used a 50g bolus but has
shown approximately equal sensitivity with a 25g bolus of lactose125 and researchers are beginning to
recognize the problematic nature of assessing lactose intolerance using a full 50g bolus of an
indigestible carbohydrate.126 It may be more practically useful to simply assess lactose intolerance
symptoms, as HBT scores are not always closely associated with lactose intolerance symptom scores.
Gut microbiome composition may be a fruitful treatment outcome to investigate. Some studies
noted a Bifidogenic effect of probiotic treatment and a reduction in lactose intolerance symptom
scores, so it may be useful to assess how long this colonic adaptation persists via a follow-up
assessment. This would help solidify the connection between probiotic treatment, intestinal
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colonization, and long-term attenuation of undesirable lactose intolerance outcomes. The duration for
which a probiotic treatment persists will depend on the resilience of the microbiota. In microbiome
research, resilience is the ability of the microbiome to return to its baseline composition following a
perturbation or alteration.127 Such alterations may be caused by foodborne illness, dietary changes, a
regimen of antibiotics, a regimen of probiotics, or other factors. In the context of a probiotic regimen,
maintaining a diet that selectively supports the probiotic bacteria could favorably reduce resilience
and lengthen the duration of treatment.128
Another noteworthy consideration is the safety of probiotic treatments. Each probiotic bacterium
may have its own considerations or risks. As mentioned above, Enterococcus faecium is potentially
pathogenic, so it should not be taken as a probiotic by those with any significant immunosuppression,
nor if the strain is found to have vancomycin resistance.107 Otherwise, no overtly pathogenic bacteria
are known to be common probiotics. In a study129 investigating the effect of a multispecies probiotic 2
times per day for 4 weeks on fecal and gastrointestinal outcomes of 298 patients with severe acute
pancreatitis, 9 subjects within the treatment group (n = 153) developed bowel ischemia and 8 of these
subjects died. The researchers offered the hypothesis that the probiotic treatment may have increased
local intestinal oxygen demand and promoted bowel ischemia,129 so risk of bowel ischemia may be a
contraindication of probiotics in the acute care setting. Other sensible contraindications may include
the presence or history of bowel perforation, which risks bacterial translocation into the host’s
systemic circulation. Otherwise, probiotics that are applied to food, in addition to a variety of
probiotic metabolites,130 are generally recognized as safe by the FDA.
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CHAPTER VII
CONCLUSION
A systematic review of 25 studies revealed a moderately strong degree of evidence that
Bifidobacterium longum, Lactobacillus delbrueckii subspecies bulgaricus, and Streptococcus
thermophilus probiotics can alleviate undesirable outcomes of lactose intolerance. There was strong
evidence that inoculated dairy products containing Lactobacillus acidophilus, Lactobacillus
delbrueckii subspecies bulgaricus, and/or Streptococcus thermophilus can also alleviate undesirable
outcomes of lactose intolerance.
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